Log in

SCYNEXIS News Headlines (NASDAQ:SCYX)

$1.12
-0.02 (-1.75 %)
(As of 10/20/2019 12:32 PM ET)
Today's Range
$1.11
Now: $1.12
$1.16
50-Day Range
$1.01
MA: $1.09
$1.23
52-Week Range
$0.35
Now: $1.12
$1.90
Volume242,657 shs
Average Volume286,319 shs
Market Capitalization$62.40 million
P/E RatioN/A
Dividend YieldN/A
Beta2.36

Headlines

SCYNEXIS (NASDAQ SCYX) News Headlines

Source:
DateHeadline
SCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program - PRNewswireSCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program - PRNewswire
www.prnewswire.com - October 10 at 1:51 PM
SCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits ProgramSCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program
finance.yahoo.com - October 10 at 1:51 PM
 Analysts Anticipate SCYNEXIS Inc (NASDAQ:SCYX) to Announce -$0.22 Earnings Per Share Analysts Anticipate SCYNEXIS Inc (NASDAQ:SCYX) to Announce -$0.22 Earnings Per Share
www.americanbankingnews.com - October 9 at 7:27 PM
SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerps Activity Against Resistant Fungal Pathogens, Including Candida auris - PRNewswireSCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris - PRNewswire
www.prnewswire.com - October 2 at 9:47 PM
SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerps Activity Against Resistant Fungal Pathogens, Including Candida aurisSCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
finance.yahoo.com - October 2 at 4:47 PM
Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet? - Yahoo FinanceDoes SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet? - Yahoo Finance
finance.yahoo.com - October 1 at 4:30 PM
Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
finance.yahoo.com - October 1 at 4:30 PM
Scynexis (SCYX) Reports Complete Last-Patient/Last-Visit Ahead of Schedule in 1st Ph. 3 Study (VANISH 303) of Oral Ibrexafungerp - StreetInsider.comScynexis (SCYX) Reports Complete Last-Patient/Last-Visit Ahead of Schedule in 1st Ph. 3 Study (VANISH 303) of Oral Ibrexafungerp - StreetInsider.com
www.streetinsider.com - September 20 at 1:57 AM
Scynexis up 11% on advancement of late-stage study of antifungal ibrexafungerp - Seeking AlphaScynexis up 11% on advancement of late-stage study of antifungal ibrexafungerp - Seeking Alpha
seekingalpha.com - September 20 at 1:57 AM
SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
finance.yahoo.com - September 20 at 1:57 AM
SCYNEXIS, Inc. to Participate in Two Upcoming Investor Conferences - Yahoo FinanceSCYNEXIS, Inc. to Participate in Two Upcoming Investor Conferences - Yahoo Finance
finance.yahoo.com - September 5 at 11:42 AM
SCYNEXIS, Inc. to Participate in Two Upcoming Investor ConferencesSCYNEXIS, Inc. to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - September 4 at 9:47 AM
Implied Volatility Surging for SCYNEXIS (SCYX) Stock Options - Yahoo FinanceImplied Volatility Surging for SCYNEXIS (SCYX) Stock Options - Yahoo Finance
finance.yahoo.com - August 22 at 9:08 AM
Implied Volatility Surging for SCYNEXIS (SCYX) Stock Options - NasdaqImplied Volatility Surging for SCYNEXIS (SCYX) Stock Options - Nasdaq
www.nasdaq.com - August 21 at 10:58 PM
Implied Volatility Surging for SCYNEXIS (SCYX) Stock OptionsImplied Volatility Surging for SCYNEXIS (SCYX) Stock Options
finance.yahoo.com - August 21 at 10:58 PM
Brookline Capital Markets Starts SCYNEXIS (SCYX) at Buy - StreetInsider.comBrookline Capital Markets Starts SCYNEXIS (SCYX) at Buy - StreetInsider.com
www.streetinsider.com - August 19 at 8:10 PM
Scynexis: 2Q Earnings Snapshot - Yahoo FinanceScynexis: 2Q Earnings Snapshot - Yahoo Finance
finance.yahoo.com - August 9 at 8:36 AM
SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update - PRNewswireSCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update - PRNewswire
www.prnewswire.com - August 7 at 11:16 PM
SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company UpdateSCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update
finance.yahoo.com - August 7 at 11:16 PM
Scynexis (SCYX) Reports Q2 Loss, Misses Revenue EstimatesScynexis (SCYX) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 7 at 11:16 PM
Scynexis (SCYX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Yahoo FinanceScynexis (SCYX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Yahoo Finance
finance.yahoo.com - August 2 at 12:56 AM
Scynexis (SCYX) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseScynexis (SCYX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - August 2 at 12:56 AM
Aegis Capital Starts SCYNEXIS (SCYX) at Buy - StreetInsider.comAegis Capital Starts SCYNEXIS (SCYX) at Buy - StreetInsider.com
www.streetinsider.com - August 1 at 12:01 AM
SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference - Yahoo FinanceSCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference - Yahoo Finance
finance.yahoo.com - July 31 at 9:11 AM
SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth ConferenceSCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference
finance.yahoo.com - July 31 at 9:11 AM
What Scynexis Trial Protocol News Says About Its Market Estimate - Seeking AlphaWhat Scynexis' Trial Protocol News Says About Its Market Estimate - Seeking Alpha
seekingalpha.com - July 26 at 7:47 AM
SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study) - PRNewswireSCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study) - PRNewswire
www.prnewswire.com - July 24 at 8:26 AM
SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
finance.yahoo.com - July 24 at 8:26 AM
Key Takeaways From A Follow-Up Phone Call With Scynexis CEO - Seeking AlphaKey Takeaways From A Follow-Up Phone Call With Scynexis CEO - Seeking Alpha
seekingalpha.com - July 20 at 8:45 AM
Scynexis: Updates To Thesis, Expecting Rebound In The Near Term - Seeking AlphaScynexis: Updates To Thesis, Expecting Rebound In The Near Term - Seeking Alpha
seekingalpha.com - July 4 at 6:59 PM
World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019 - PRNewswireWorld-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019 - PRNewswire
www.prnewswire.com - June 27 at 8:29 AM
World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
finance.yahoo.com - June 25 at 11:53 AM
Imagine Owning SCYNEXIS (NASDAQ:SCYX) And Trying To Stomach The 84% Share Price Drop - Yahoo FinanceImagine Owning SCYNEXIS (NASDAQ:SCYX) And Trying To Stomach The 84% Share Price Drop - Yahoo Finance
finance.yahoo.com - June 19 at 8:02 PM
Imagine Owning SCYNEXIS (NASDAQ:SCYX) And Trying To Stomach The 84% Share Price DropImagine Owning SCYNEXIS (NASDAQ:SCYX) And Trying To Stomach The 84% Share Price Drop
finance.yahoo.com - June 19 at 8:02 PM
Scynexis And The Fungal Economy - Seeking AlphaScynexis And The Fungal Economy - Seeking Alpha
seekingalpha.com - June 17 at 8:09 PM
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development - PRNewswireSCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development - PRNewswire
www.prnewswire.com - June 14 at 8:38 AM
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical DevelopmentSCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
finance.yahoo.com - June 14 at 8:38 AM
SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal InfectionsSCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections
finance.yahoo.com - June 5 at 7:00 PM
SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp - PRNewswireSCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp - PRNewswire
www.prnewswire.com - May 30 at 6:46 PM
SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of IbrexafungerpSCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp
finance.yahoo.com - May 30 at 6:46 PM
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo FinanceScynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 10 at 8:20 AM
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue EstimatesScynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 9 at 8:16 AM
SCYNEXIS Reports First Quarter 2019 Financial Results and Provides Company Update - PRNewswireSCYNEXIS Reports First Quarter 2019 Financial Results and Provides Company Update - PRNewswire
www.prnewswire.com - May 8 at 7:40 PM
Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo FinanceScynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
finance.yahoo.com - May 8 at 8:19 AM
Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - NasdaqScynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Nasdaq
www.nasdaq.com - May 7 at 7:04 PM
Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
finance.yahoo.com - May 7 at 7:04 PM
SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC) - PRNewswireSCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC) - PRNewswire
www.prnewswire.com - May 6 at 7:43 PM
SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
finance.yahoo.com - May 6 at 7:43 PM
SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) - PRNewswireSCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) - PRNewswire
www.prnewswire.com - May 2 at 8:21 AM
SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) - Yahoo FinanceSCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) - Yahoo Finance
finance.yahoo.com - May 1 at 7:31 PM
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel